Research news
- 25 July 2008
New partnership announced to test drug for Duchenne muscular dystrophy UK-based biotechnology company Summit Corporation plc announced a partnership this week with US pharmaceutical company BioMarin. - 22 July 2008
Another step forward for muscle stem cells Research lead by Amy J. Wagers at Harvard University, USA, has shown promise for isolating muscle stem cells, a step towards making cell transplantation a possible treatment for muscle diseases. - 30 May 2008
Dystrophic hearts treated with viagra Research update about the news that viagra could help treat the hearts of people with Duchenne and Becker muscular dystrophy. - 20 March 2008
PTC Therapeutics announce new clinical trial PTC Therapeutics has announced it will begin a long-term clinical trial in patients with Duchenne and Becker muscular dystrophies. - 16 November 2007
Scientists reverse myotonia in a mouse model of myotonic dystrophy Researchers from the University of Rochester Medical Center have been able to reverse the symptoms of myotonia in a mouse model for myotonic dystrophy. - 16 October 2007
New mutations causing congenital myopathies Professor Francesco Muntoni and his colleagues at Imperial College and the Hammersmith hospital have found nine novel mutations that can cause congenital myopathies. This result was published in the prominent journal, Brain, earlier this year. - 7 September 2007
HFEA reaches decision on cybrid embryo research The Human Fertilisation and Embryology Authority (HFEA) yesterday reached a decision to allow the possible use of “cybrid” embryos for research. - 27 July 2007
New mechanism causing facioscapulohumeral muscular dystrophy proposed Professor Hewitt and colleagues at the University of Nottingham have published an evolutionary study which sheds new light onto the genetic defect leading to facioscapulohumeral muscular dystrophy - 6 July 2007
Santhera licenses Omigapil for treatment of rare neuromuscular disorders Santhera Pharmaceuticals this week announced a licensing agreement with Novartis to test their compound omigapil for the treatment of congenital muscular dystrophy. - 5 July 2007
Not all muscle stem cells are equal Researchers have revealed new evidence that not all muscle stem cells – or satellite cells – have the same biological characteristics.
